Loading organizations...
§ Private Profile · London, England, United Kingdom
A biopharmaceutical company developing personalized T cell therapies for solid tumors using its PELEUS platform.
Achilles Therapeutics is a London-based clinical-stage biopharmaceutical company that develops personalized precision T cell therapies targeting clonal neoantigens to treat solid tumors. The publicly traded enterprise utilizes its proprietary AI-powered bioinformatics platform, known as PELEUS, to identify unique cancer mutations and manufacture patient-specific immunotherapies for oncology indications like melanoma and non-small cell lung cancer. Operating with a workforce of approximately 215 employees, the firm raised $175.5 million during its 2021 NASDAQ initial public offering and previously secured a £100 million Series B financing round before entering liquidation proceedings in March 2025. Throughout its operational history, the biotechnology company received significant financial backing from prominent institutional investors including Syncona, RA Capital Management, Forbion, and Cancer Research Technology. Achilles Therapeutics was originally founded in 2016 by Charles Swanton, Sergio Quezada, Karl Peggs, Mark Lowdell, and Mark Linthicum.
Achilles Therapeutics has raised $206.8M across 3 funding rounds.
Achilles Therapeutics has raised $206.8M in total across 3 funding rounds.
Achilles Therapeutics has raised $206.8M across 3 funding rounds. Most recently, it raised $69.8M Series C in November 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 19, 2020 | $69.8M Series C | Boxer Capital, OrbiMed | Forbion, Invus, Perceptive Advisors, RA Capital Management, Redmile Group, Syncona | Announced |
| Sep 3, 2019 | $120.8M Series B | Derek Dirocco | Rogier Rooswinkel, Invus, Perceptive Advisors, Redmile Group, Martin Murphy | Announced |
| Nov 1, 2016 | $16.1M Venture Round | Cancer Research Horizons, Syncona, UCL | Francis Crick Institute, UCL Business | Announced |
Achilles Therapeutics has raised $206.8M in total across 3 funding rounds.
Achilles Therapeutics's investors include Boxer Capital, OrbiMed, Forbion, Invus, Perceptive Advisors, RA Capital Management, Redmile Group, Syncona, Derek DiRocco, Rogier Rooswinkel, Martin Murphy, Cancer Research Horizons.